The ICHOM Standard Set for Localized Prostate Cancer is the result of hard work by a group of leading physicians, measurement experts and patients. It is our recommendation of the outcomes that matter most to patients with Localized Prostate Cancer. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of their patients.
1 Recorded via the Clavien-Dindo-Classification
2 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
3 Recommend to track via the Expanded Prostate Cancer Index Composite (EPIC)-26
Standard Set materials have moved to ICHOM Connect and are still available free of charge. Please log in or register to gain access to unlimited ICHOM resources at a single click of a button. There, you can also indicate your interest in receiving updates about and implementing the Standard Set.
Flyer – a brief overview of the most important outcomes for patients relating to this ICHOM Standard Set.
Reference Guide – a complete overview of the ICHOM Standard Set, including definitions for each measure and selected PROM instruments, time points for collection, and associated risk factors.
Data Dictionary – an index of the outcomes and case-mix variables included in the standard set, how to code them, and the information you need to collect when implementing the outcomes in practice.
Kim Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University. South Australien Prostate Cancer Clinical Outcomes
Ian Roos* | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria
Hartwig Huland | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Thomas Wiegel | University Hospital Ulm
Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO
Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society
Jacob Ramon | Sheba Medical Center
Alberto Briganti | Vita-Salute San Raffaele University Hospital
Chris Bangma | Erasmus Medical Center
Anna Bill-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden
Adam Glaser | Leeds Teaching Hospitals NHS Trust
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre
Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Adam Kibel | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Anthony D’Amico | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Neil Martin | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Michael Blute | Massachusetts General Hospital
Howard Sandler | Cedars-Sinai Medical Center
Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Nancy Mendenhall | University of Florida Proton Therapy Institute
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital
Stay up to date
To receive updates about this standard set, including new versions, please click on the box below.